Clinical Trial: A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia

U.S., Jan. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07327359) titled 'A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia' on Dec. 04, 2025.

Brief Summary: This study is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of OLX72021 in medically healthy men with mild to moderate androgenetic alopecia.

Study Start Date: Dec. 04, 2025

Study Type: INTERVENTIONAL

Condition: Androgenetic Alopecia (AGA)

Intervention: DRUG: OLX72021

Low Dose

DRUG: OLX72021

Mid Dose

DRUG: OLX72021

High Dose

DRUG: Placebo

Placebo

Recruitment Status: RECRUITING

Sponsor: Olix Pharmaceuticals, Inc.

Disclaimer: Curated by HT Syndication....